세계의 환자 유래 이종 이식편(PDX) 모델 시장 : 산업 규모, 동향, 기회, 예측 - 종양 유형별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tumor Type, By Type, By End-User, By Region and Competition, 2020-2030F
세계의 환자 유래 이종 이식편(PDX) 모델 시장은 2024년 22억 6,000만 달러로 평가되었고, 예측 기간 동안 CAGR 9.98%로 성장할 전망이며, 2030년에는 40억 달러에 이를 것으로 예측됩니다.
이 성장의 원동력이 되고 있는 것은 암 연구나 맞춤형 의료에 있어서 PDX 모델 역할의 확대입니다. 인간 종양 조직을 면역결핍 마우스에 이식함으로써 제작되는 PDX 모델은 인간 종양의 거동을 충실히 반영하는 임상적으로 적절한 플랫폼을 제공하여 암의 진행 연구나 새로운 치료법의 평가에 매우 귀중한 것이 되고 있습니다. 세계의 암 이환율이 상승함에 따라 정확하고 예측 가능한 전임상 모델의 필요성은 점점 높아지고 있습니다. PDX 모델은 원래 종양의 유전적 및 분자적 특징을 유지하고 있으며, 연구자에게 약효 평가 및 표적 치료 개발의 보다 정밀한 도구를 제공합니다. 환자 개개인의 유전자 프로파일에 맞춰 치료법을 조정하는 개별화 종양학으로의 전환은 PDX 모델의 수요를 더욱 끌어올리고 있습니다. 이 모델들은 과학자나 임상의사가 환자 유래 종양으로 치료법을 테스트하는 것을 가능하게 하고, 치료 반응을 예측하며, 보다 효과적이고 개별화된 치료 전략을 추진합니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
22억 6,000만 달러 |
| 시장 규모(2030년) |
40억 달러 |
| CAGR(2025-2030년) |
9.98% |
| 급성장 부문 |
유방암 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
암 이환율 증가 및 미충족 요구
주요 시장 과제
불균일성 및 편차
주요 시장 동향
맞춤형 의료에 대한 관심 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 환자 유래 이종 이식편(PDX) 모델 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 종양 유형별(폐암, 췌장암, 전립선암, 유방암, 기타 암)
- 유형별(마우스, 래트)
- 최종 사용자별(입원 환자 설정, 커뮤니티 설정)
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 환자 유래 이종 이식편(PDX) 모델 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 환자 유래 이종 이식편(PDX) 모델 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 환자 유래 이종 이식편(PDX) 모델 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 환자 유래 이종 이식편(PDX) 모델 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카 환자 유래 이종 이식편(PDX) 모델 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향 및 발전
제13장 PESTEL 분석
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Charles River Laboratories Inc.
- The Jackson Laboratory
- Crown Bioscience,Inc.
- Altogen Labs
- Envigo
- WuxiAppTec
- Oncodesign
- Hera BioLabs
- XenTech
- Abnova Corporation
제16장 전략적 제안
제17장 기업 소개 및 면책사항
AJY
The Global Patient-Derived Xenograft (PDX) Model Market was valued at USD 2.26 billion in 2024 and is projected to reach USD 4.00 billion by 2030, growing at a CAGR of 9.98% during the forecast period. This growth is being driven by the model's expanding role in cancer research and personalized medicine. PDX models, created by implanting human tumor tissue into immunodeficient mice, offer a clinically relevant platform that closely mirrors human tumor behavior, making them invaluable in studying cancer progression and evaluating new therapies. As global cancer incidence rises, the need for accurate and predictive preclinical models becomes increasingly critical. PDX models preserve the genetic and molecular characteristics of original tumors, offering researchers a more precise tool for evaluating drug efficacy and developing targeted treatments. The shift towards personalized oncology, which tailors therapies to the individual genetic profiles of patients, is further boosting demand for PDX models. These models enable scientists and clinicians to test therapies on patient-derived tumors, predicting treatment responses and advancing more effective and individualized care strategies.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 2.26 Billion |
| Market Size 2030 | USD 4.00 Billion |
| CAGR 2025-2030 | 9.98% |
| Fastest Growing Segment | Breast Cancer |
| Largest Market | North America |
Key Market Drivers
Rising Cancer Incidence and Unmet Medical Needs
The increasing global burden of cancer is a key factor fueling the growth of the PDX model market. With cancer expected to see a 70% increase in new cases over the next two decades, the urgency for innovative treatment options has intensified. PDX models replicate the complexity and heterogeneity of human tumors, making them ideal for understanding tumor biology and testing therapeutic agents. These models maintain critical aspects of patient tumors-such as genetic diversity, microenvironment interactions, and treatment resistance-allowing researchers to evaluate treatment outcomes with greater accuracy. As cancer research shifts towards precision-based therapies, the utility of PDX models in identifying and validating new drug candidates has become even more pronounced. Their ability to model real-world tumor behavior supports drug development pipelines and helps address significant unmet medical needs.
Key Market Challenges
Heterogeneity and Variability
Despite their advantages, PDX models face limitations due to the inherent heterogeneity of human tumors. Tumor samples differ significantly between patients, even within the same cancer type, complicating efforts to create universally representative models. This variability can influence drug response outcomes, affecting the reliability of data and complicating clinical translation. While PDX models retain many biological features of the original tumors, they cannot capture the full extent of molecular and cellular complexity. Furthermore, the engraftment process itself may alter tumor characteristics over time. These limitations highlight the need for ongoing refinement in PDX model development to ensure broader applicability and predictive accuracy in therapeutic evaluation.
Key Market Trends
Rising Interest in Personalized Medicine
The growing adoption of personalized medicine is a major trend shaping the PDX model market. Personalized treatment strategies require models that can mimic patient-specific tumor biology. PDX models allow for the creation of "avatar mice"-animal models implanted with tumor samples from individual patients-which are used to test a range of therapeutic options. These models help clinicians determine the most effective course of treatment, reducing adverse effects and improving outcomes. The integration of PDX models into clinical research has accelerated drug development and enhanced the success rate of oncology trials by providing patient-relevant data. As the pharmaceutical industry increasingly embraces targeted therapies, PDX models are expected to play a crucial role in refining therapeutic selection and reducing trial-and-error approaches in cancer treatment.
Key Market Players
- Charles River Laboratories Inc.
- The Jackson Laboratory
- Crown Bioscience, Inc.
- Altogen Labs
- Envigo
- WuxiAppTec
- Oncodesign
- Hera BioLabs
- XenTech
- Abnova Corporation
Report Scope:
In this report, the Global Patient-Derived Xenograft Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Patient-Derived Xenograft Model Market, By Tumor Type:
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Breast Cancer
- Other Cancer
Patient-Derived Xenograft Model Market, By End User:
- Inpatient Settings
- Community Settings
Patient-Derived Xenograft Model Market, By Type:
Patient-Derived Xenograft Model Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Patient-Derived Xenograft Model Market.
Available Customizations:
Global Patient-Derived Xenograft Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Patient-Derived Xenograft Model Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer)
- 5.2.2. By Type (Mice, Rats)
- 5.2.3. By End-User (Inpatient Settings, Community Settings)
- 5.2.4. By Company (2024)
- 5.2.5. By Region
- 5.3. Market Map
6. North America Patient-Derived Xenograft Model Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Tumor Type
- 6.2.2. By Type
- 6.2.3. By End-user
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Patient-Derived Xenograft Model Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Tumor Type
- 6.3.1.2.2. By Type
- 6.3.1.2.3. By End-user
- 6.3.2. Mexico Patient-Derived Xenograft Model Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Tumor Type
- 6.3.2.2.2. By Type
- 6.3.2.2.3. By End-user
- 6.3.3. Canada Patient-Derived Xenograft Model Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Tumor Type
- 6.3.3.2.2. By Type
- 6.3.3.2.3. By End-user
7. Europe Patient-Derived Xenograft Model Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Tumor Type
- 7.2.2. By Type
- 7.2.3. By End-user
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Patient-Derived Xenograft Model Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Tumor Type
- 7.3.1.2.2. By Type
- 7.3.1.2.3. By End-user
- 7.3.2. Germany Patient-Derived Xenograft Model Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Tumor Type
- 7.3.2.2.2. By Type
- 7.3.2.2.3. By End-user
- 7.3.3. United Kingdom Patient-Derived Xenograft Model Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Tumor Type
- 7.3.3.2.2. By Type
- 7.3.3.2.3. By End-user
- 7.3.4. Italy Patient-Derived Xenograft Model Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Tumor Type
- 7.3.4.2.2. By Type
- 7.3.4.2.3. By End-user
- 7.3.5. Spain Patient-Derived Xenograft Model Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Tumor Type
- 7.3.5.2.2. By Type
- 7.3.5.2.3. By End-user
8. Asia-Pacific Patient-Derived Xenograft Model Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Tumor Type
- 8.2.2. By Type
- 8.2.3. By End-user
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Patient-Derived Xenograft Model Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Tumor Type
- 8.3.1.2.2. By Type
- 8.3.1.2.3. By End-user
- 8.3.2. India Patient-Derived Xenograft Model Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Tumor Type
- 8.3.2.2.2. By Type
- 8.3.2.2.3. By End-user
- 8.3.3. South Korea Patient-Derived Xenograft Model Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Tumor Type
- 8.3.3.2.2. By Type
- 8.3.3.2.3. By End-user
- 8.3.4. Japan Patient-Derived Xenograft Model Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Tumor Type
- 8.3.4.2.2. By Type
- 8.3.4.2.3. By End-user
- 8.3.5. Australia Patient-Derived Xenograft Model Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Tumor Type
- 8.3.5.2.2. By Type
- 8.3.5.2.3. By End-user
9. South America Patient-Derived Xenograft Model Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Tumor Type
- 9.2.2. By Type
- 9.2.3. By End-user
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Patient-Derived Xenograft Model Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Tumor Type
- 9.3.1.2.2. By Type
- 9.3.1.2.3. By End-user
- 9.3.2. Argentina Patient-Derived Xenograft Model Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Tumor Type
- 9.3.2.2.2. By Type
- 9.3.2.2.3. By End-user
- 9.3.3. Colombia Patient-Derived Xenograft Model Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Tumor Type
- 9.3.3.2.2. By Type
- 9.3.3.2.3. By End-user
10. Middle East and Africa Patient-Derived Xenograft Model Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Tumor Type
- 10.2.2. By Type
- 10.2.3. By End-user
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Patient-Derived Xenograft Model Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Tumor Type
- 10.3.1.2.2. By Type
- 10.3.1.2.3. By End-user
- 10.3.2. Saudi Arabia Patient-Derived Xenograft Model Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Tumor Type
- 10.3.2.2.2. By Type
- 10.3.2.2.3. By End-user
- 10.3.3. UAE Patient-Derived Xenograft Model Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Tumor Type
- 10.3.3.2.2. By Type
- 10.3.3.2.3. By End-user
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. Competitive Landscape
- 15.1. Charles River Laboratories Inc.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. The Jackson Laboratory
- 15.3. Crown Bioscience,Inc.
- 15.4. Altogen Labs
- 15.5. Envigo
- 15.6. WuxiAppTec
- 15.7. Oncodesign
- 15.8. Hera BioLabs
- 15.9. XenTech
- 15.10. Abnova Corporation
16. Strategic Recommendation
17. About Us & Disclaimer
